Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

Wnt signaling activation impacts the response to melanoma treatment.

Patients with stage 3 kidney disease cured of hepatitis C virus experienced an improvement in kidney function following treatment.

Company harnesses CRISPR-based gene editing technology as it enters human clinical trials to treat HIV.

Top news of the day from across the health care landscape.

New drug approval highlights the need for value-based payment models for Medicare and Medicaid.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Mvasi is indicated to treat adult patients with certain types of colorectal, lung, brain, kidney, and cervical cancers.

Bevacizumab-awwb, a biosimilar to Avastin, approved to treat several cancer types.

The National Association of Specialty Pharmacy Annual Meeting and Educational Conference has a full slate of events in addition to a packed agenda.

SB239 seeks to reduce the penalty for knowingly exposing sexual partners to HIV to a misdemeanor.

Patients with drug-resistant melanoma treated with a herpes virus-pembrolizumab drug combination showed a complete or partial response.

Deaf patients with cancer report difficulties understanding treatments, procedures, and risks related to cancer.

Top news of the day from across the health care landscape.

Sofosbuvir may help improve the kidney function of some patients with hepatitis C virus.

Sometimes lending an ear can be the best medicine.

The current specialty pharmacy landscape is constantly evolving, requiring a collaborative environment to meet the needs of patients.

Nerlynx is indicated to treat early-stage HER2-positive breast cancer following trastuzumab-based therapy.

Screening all chromosomes could identify additional prenatal abnormalities.

Device may reveal how to stop cancer cells from spreading.

Top news of the day from across the health care landscape.

No differences in the effects of screening versus no screening found between 2 prostate cancer trials.

Rituxan is used to treat blood cancers and immunological diseases.

Investigational trastuzumab biosimilar shows promise as potential lower cost treatment option to Herceptin for breast cancer and gastric cancer.

A bloated hepatitis C drug marketplace causes manufacturer to focus on hepatitis B.

Findings suggest daily use of Truvada is safe and effective among males aged 15 to 17 years.

A tissue analyzing pen could revolutionize cancer treatment by improving diagnosis.

Study findings support research demonstrating endoxifen better inhibits tumor growth compared with tamoxifen.